Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
This goal of this clinical research study is to learn if the combination of methotrexate,
pegylated-L-asparaginase, vincristine, and dexamethasone (also rituximab in some patients)
can help to control ALL that has not responded to previous treatment or has come back after a
response or chronic myeloid leukemia (CML).
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Leadiant Biosciences, Inc. Sigma Tau Pharmaceuticals, Inc.